Hot Features
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopa... Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -6.45161290323 | 0.62 | 0.62 | 0.58 | 3843 | 0.58884679 | CS |
| 4 | 0.02 | 3.57142857143 | 0.56 | 0.62 | 0.56 | 27380 | 0.57306442 | CS |
| 12 | 0.1 | 20.8333333333 | 0.48 | 0.64 | 0.44 | 25156 | 0.54998606 | CS |
| 26 | -0.01 | -1.69491525424 | 0.59 | 0.66 | 0.44 | 21048 | 0.55989608 | CS |
| 52 | -0.14 | -19.4444444444 | 0.72 | 0.88 | 0.44 | 22936 | 0.66750266 | CS |
| 156 | -0.15 | -20.5479452055 | 0.73 | 1.06 | 0.44 | 19987 | 0.68971005 | CS |
| 260 | 0.18 | 45 | 0.4 | 1.06 | 0.375 | 19248 | 0.65929295 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.